ARTICLE | Company News
NEOT subsidiary acquires cancer compound
September 6, 2001 7:00 AM UTC
NeoOnocRx, a subsidiary of NeoTherapeutics (NEOT) acquired worldwide rights to develop and market satraplatin, a platinum anti-cancer compound (JM-216) from Johnson Matthey (JMPLY; LSE:JMAT). NEOT exp...